EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications

MacKenzie Wyatt iD, Alexandra Quinn, Lincoln Shade, Meghan McGarry

International Journal of Neonatal Screening · 30.07.2025 · 11 (3) · 60

DOI: 10.3390/ijns11030060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 30.07.2025. Verfasst von MacKenzie Wyatt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98105, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Cystic Fibrosis Foundation, National Institute of Neurological Disorders and Stroke (NINDS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An unintended consequence of cystic fibrosis (CF) newborn screening (NBS) is the identification of infants with a positive NBS who do not meet the diagnostic criteria for CF (two CF-causing variants and/or sweat chloride > 60 mmol/L). This indeterminate diagnosis is called cystic fibrosis transmembrane conductance regulator (CFTR)-related metabolic syndrome (CRMS) or CF screen positive, inconclusive diagnosis (CFSPID). CRMS/CFSPID occurs when it is not clearly known whether CFTR variants are disease-causing. In 2024, the CFTR2 classification of many CFTR variants was changed from unknown significance to either CF-causing variants or variants of varying clinical consequences (VVCCs). We conducted a meta-analysis of CRMS/CFSPID cases from manuscripts to describe how the diagnoses would change using two different variant panels: (1) only CF-causing CFTR variants (PanelCF-causing) and (2) CF-causing variants and VVCCs (PanelCF-causing+VVCCs). Using the PanelCF-causing, 8.7% had two CF-causing variants (reclassified as CF), while 91.3% had less than two CF-causing variants (reclassified as Undetected). Using the PanelCF-causing+VVCCs, 51.4% had either two VVCCs or one VVCC with one CF-causing variant detected (reclassified as CRMS/CFSPD), 39.9% had less than two CF-causing variants detected (reclassified as Undetected), and 8.7% had two CF-causing variants (reclassified as CF). In conclusion, using the updated CFTR2 classification of CFTR variants significantly decreases the number of children with CRMS/CFSPID and gives a definitive diagnosis of CF to some children while not detecting as many children who are unlikely to develop CF.

Schlagwörter

Stichwörter der Autor:innen

CF screen positive inconclusive diagnosisCFSPIDCRMSCRMS/CFSPIDcystic fibrosiscystic fibrosis transmembrane conductance regulator genecystic fibrosis transmembrane conductance regulator-related metabolic syndromegenetic testingnewborn screeningsweat chloride

Autor:innen und Institutionen

  • Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98105, USA.
  • Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, WA 98101, USA.
  • Institute for Biomedical Informatics, Multidisciplinary Science, University of Kentucky, 725 Rose St Building, Suite 230, Lexington, KY 40536, USA.

ORCID-Profile: MacKenzie Wyatt

Förderung

  • NHLBI NIH HHS
  • Cystic Fibrosis Foundation
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • NIH HHS
  • NINDS NIH HHS
  • Cystic Fibrosis Foundation (CFF) Clinical Fellowship Award
  • Rosenfeld Funds
  • Corkery Endowment

Zitieren

APA

Wyatt, M., Quinn, A., Shade, L., & McGarry, M. (2025). Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications. International Journal of Neonatal Screening, 11(3), 60. https://doi.org/10.3390/ijns11030060

Vancouver

Wyatt M, Quinn A, Shade L, McGarry M. Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications. International Journal of Neonatal Screening. 2025;11(3):60. doi:10.3390/ijns11030060

BibTeX
@article{Wyatt2025,
  author = {Wyatt, MacKenzie and Quinn, Alexandra and Shade, Lincoln and McGarry, Meghan},
  title = {Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications},
  journal = {International Journal of Neonatal Screening},
  year = {2025},
  volume = {11},
  number = {3},
  pages = {60},
  doi = {10.3390/ijns11030060}
}
Kostenlos starten →